European Psychiatry
April 1, 2025
P. Andres-Olivera, Janis V. de la Iglesia, E. Dominguez-Alvarez et al.
Introduction Psilocybin, a psychedelic compound, has shown potential in treating depression, especially in cases resistant to conventional treatments. This study systematically reviews the scientific literature to assess its efficacy and safety. Objectives The main objective of this study is to evaluate the therapeutic effects of psilocybin for the treatment of depressive disorder through a...
Microbial Biotechnology
April 1, 2025
Zhangrao Huang, Yongpeng Yao, Rong Di et al.
12 citations
ABSTRACT Psilocybin, a tryptamine‐derived alkaloid, has been granted Breakthrough Therapy designation by the U.S. FDA for treatment‐resistant depression, underscoring its clinical importance. Therefore, sustainable and economic production is urgently needed. Manufacturing of psilocybin in Escherichia coli has drawn great attention. However, due to the low expression and activity of the...
BMJ Open
April 1, 2025
Vanessa L. Beesley, Tom Kennedy, Fiona Maccallum et al.
2 citations
Introduction Prolonged grief disorder (PGD) represents a substantial public health issue, especially in oncology settings where it affects up to 30% of bereaved carers. Current best-practice treatments are lengthy, and up to 50% of participants have persistent PGD. Building on encouraging recent research with psychedelic-assisted therapies, the Psilocybin-Assisted suppoRtive psychoTherapy IN...
Molecular Psychiatry
April 1, 2025
Devon Stoliker, Katrin H. Preller, Leonardo Novelli et al.
19 citations
Visual alterations under classic psychedelics can include rich phenomenological accounts of eyes-closed imagery. Preclinical evidence suggests agonism of the 5-HT2A receptor may reduce synaptic gain to produce psychedelic-induced imagery. However, this has not been investigated in humans. To infer the directed connectivity changes to visual connectivity underlying psychedelic visual imagery in...
JAMA Network Open
April 1, 2025
Jenna Matsukubo, Sarah Dickson, Jennifer Xiao et al.
7 citations
Importance There is growing societal interest in and use of psilocybin. While psilocybin in Canada is illegal outside of clinical trials, there have been anecdotal reports of increasing access via unregulated online purchases and retail dispensaries. Objective To describe access to and the characteristics of psilocybin dispensaries across Canada and the health claims and warnings made on...
Cureus
April 1, 2025
Ciara Mimms, Kassandra Sotelo, Abdul Saboor Khaliq
1 citation
This systematic review explores the comparative efficacy and functional outcomes of psychedelic-assisted therapies in the management of treatment-resistant depression (TRD). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive literature search was conducted across PubMed, Scopus, and Web of Science for randomized controlled...
March 31, 2025
Ryan J. Keenan, Rezaul Haque, Xianbo Jin et al.
preprint
Abstract Prolonged obesity induces enduring structural changes within neural circuits that contribute to maintaining the body at an elevated/obese body weight. These circuits regulate various mechanisms which can inhibit extreme or persistent weight loss. Therefore, a potential therapeutic strategy to facilitate weight loss is to promote structural plasticity within the brain. Psychedelic...
Psychological Medicine
March 31, 2025
Otto Simonsson, Simon B. Goldberg, Walter Osika et al.
16 citations
BACKGROUND: Findings from contemporary clinical trials suggest that psychedelics are generally safe and may be effective in the treatment of various psychiatric disorders. However, less is known about the risks associated with psychedelic use outside of medically supervised contexts, particularly in populations that are typically excluded from participation in clinical trials. METHODS:...
Journal of Psychoactive Drugs
March 31, 2025
Samuel Thomson, Nikos Thomacos
11 citations
Psychedelic-assisted therapy is gaining recognition for its potential to enhance human functioning. While most research has focused on psychedelic' therapeutic use for mental illness, this review applies the PERMA Theory of Well-Being to systematically examine their role in enhancing well-being in healthy individuals. The final search of five academic databases was conducted on February 4,...
Journal of Psychopharmacology
March 31, 2025
Tomislav Majić, Timo Torsten Schmidt, Anna Gröticke et al.
4 citations
Background: Classic psychedelics such as psilocybin and lysergic acid diethylamide are anecdotally associated with the phenomenon of “psychedelic afterglow,” a set of predominantly pleasant, temporary psychological effects reported after the acute effects have subsided. Since post-acute effects are crucial for the therapeutic use of psychedelics, an instrument to systematically assess subacute...
The International Journal of Neuropsychopharmacology
March 29, 2025
Michal Lazar, Michal Brownstien, Alexander Botvinnik et al.
3 citations
Abstract Background SAPAP3-knockout (SAPAP3-KO) mice develop excessive self-grooming behavior at 4-6 months of age, serving as a model for obsessive-compulsive disorder (OCD). Given that anxiety often precedes OCD diagnosis in humans, this study investigated whether juvenile SAPAP3-KO mice exhibit anxiety-like behaviors before developing the self-grooming phenotype, and whether such behaviors...
The Brown University Psychopharmacology Update
March 27, 2025
Adults with alcohol use disorder who received two sessions of psilocybin‐assisted therapy demonstrated personality shifts toward normalization of abnormal trait expression, a secondary analysis of a randomized trial has found. A decrease in impulsiveness was found to be associated with reduced drinking post‐treatment, with the strongest effect for psilocybin‐treated individuals who had engaged...
Psychopharmacology
March 26, 2025
Laura Ley, Matthias E. Liechti, Anna M Becker et al.
3 citations
Little is known about motives of healthy volunteers to participate in psychedelic trials and how they appraise their study experience retrospectively. This paper explored reasons why healthy people register for psychedelic trials, factors that they considered to contribute to either positive or negative study experiences, and under which circumstances they would seek a psychedelic experience...
Translational Psychiatry
March 25, 2025
Brian H Silverstein, Nicholas Kolbman, Amanda Nelson et al.
8 citations
Psilocybin produces an altered state of consciousness in humans and is associated with complex spatiotemporal changes in cortical networks. Given the emphasis on rodent models for mechanistic studies, there is a need for characterization of the effect of psilocybin on cortex-wide network dynamics. Previous electroencephalographic studies of psychedelics in rodents have primarily used sparse...
The Canadian Journal of Psychiatry
March 25, 2025
Noah Chisamore, Erica Kaczmarek, Zoe Doyle et al.
1 citation
Objective: To compare changes in depression, anxiety, and suicidality symptoms after a single 25 mg oral dose of psilocybin between treatment-resistant depression participants not on antidepressants at screening to participants that discontinued antidepressant medications leading up to receiving psilocybin-assisted psychotherapy (PAP). Methods: Participants (n = 27) received at least one 25 mg...
Pharmaceutics
March 25, 2025
Shakila Meshkat, Huda Al-Shamali, Argyrios Perivolaris et al.
22 citations
Background: Psilocybin has shown promise in therapeutic applications for mental disorders. Understanding the pharmacokinetics of psilocybin and its active metabolite psilocin is crucial for optimizing its clinical use and minimizing adverse effects. Methods: This systematic review involved a comprehensive search across MEDLINE, APA PsycINFO, and Embase databases, from inception to December...
Pharmaceuticals
March 23, 2025
Gregory Ian Robinson, Marta Gerasymchuk, Timur Zanikov et al.
4 citations
Background/Objectives: Liver inflammatory diseases are a major global health burden and are often exacerbated by inflammation driven by lipopolysaccharides (LPS) through toll-like receptor 4 signaling. This study evaluates the anti-inflammatory effects of psilocybin and eugenol in an LPS-induced liver inflammation model in C57BL/6J mice. Methods: Mice were treated with psilocybin (0.88 mg/kg)...
Journal of Humanistic Psychology
March 22, 2025
M. Cirillo
There are substantial differences between the current FDA and research-driven approach to psychedelic use in Western cultures and traditional uses among Indigenous peoples. While the research-driven, evidence-based approach to identifying risks and benefits for particular conditions used in the United States and elsewhere helps ensure safety and efficacy, there is a risk of failing to...
Nature Communications
March 22, 2025
Chunyan Meng, Wenting Guo, Chuan Xiao et al.
4 citations
Psilocybin shows significant therapeutic potential for psilocybin-assisted psychotherapy in addressing various psychiatric conditions. The biosynthetic approach promises rapid and efficient production of psilocybin. Understanding the enzymes that contribute to the biosynthesis of psilocybin can enhance its production process. In this study, we elucidate the crystal structures of...
Advanced Science
March 20, 2025
Sung‐hyun Kim, Sumin Yang, Jeehye Jung et al.
5 citations
Abstract Mental disorders are a representative type of brain disorder, including anxiety, major depressive depression (MDD), and autism spectrum disorder (ASD), that are caused by multiple etiologies, including genetic heterogeneity, epigenetic dysregulation, and aberrant morphological and biochemical conditions. Psychedelic drugs such as psilocybin and lysergic acid diethylamide (LSD) have...